Choose a country and language

United States Flag United States
United Kingdom Flag United Kingdom
Netherlands Flag Netherlands
Germany Flag Germany
Norway Flag Norway
Sweden Flag Sweden
For ALL other countries, please click here.
Patients & Caregivers Healthcare Providers

The nerve to expect more. The nerve to redefine patient expectations.

The VNS Therapy® System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications

VNS Therapy® treatment in adult patients

Medication alone is not enough in managing drug-resistant epilepsy

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom1

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures2

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years3,4

The nerve to enable adult patients to overcome seizures

The latest generation of VNS Therapy® with AutoStim* is designed with seizure control in mind—with the ability to customize treatment to meet the needs of your patients with drug-resistant epilepsy (DRE)

*Only available in models 106 and 1000

VNS Therapy™ de-intensifies seizures and improves patient recovery

VNS Therapy® de-intensifies seizures and improves post-ictal recovery

Significant improvements start early and increase over time8

 

Responsive VNS Therapy™ with AutoStim* provides additional seizure reduction after replacement of a conventional VNS Therapy device

Responsive VNS Therapy® with AutoStim* provides additional reduction in seizure frequency after replacement of a conventional VNS Therapy device6

Responsive VNS Therapy devices include Normal Mode, Magnet Mode, and AutoStim Mode.  Conventional VNS Therapy devices include Normal Mode and Magnet Mode.

 

*Only available in models 106 and 1000

VNS Therapy® response improves over time with a 76% mean reduction in seizures at 10 years

VNS Therapy® response improves over time with a 76% mean reduction in seizures at 10 years

Mean reduction in seizure frequency7

The nerve to improve a patient’s quality of life

Your patients with DRE deserve the opportunity to live without the constant fear of having
a seizure—and VNS Therapy is proven to help many of them do just that. VNS Therapy has
shown to offer quality-of-life (QoL) benefits that can help patients overcome the obstacles
they face in everyday life.

3 out of 4 patients experienced improvements in overall QoL

3 out of 4 patients experienced improvements in overall QoL8

Cognitive and psychosocial benefits include improvements in†:

  • Memory
  • Verbal skills
  • Mood changes
  • Alertness

†N=1194, maximum achieved follow-up range of 24–48 months.

VNS Therapy® significantly reduces depressive symptoms in DRE patients

VNS Therapy® significantly reduces depressive symptoms in DRE patients

Change in depressive symptom severity9

Change in MADRS score: 38% reduction after VNS Therapy

Change in BDI score: 42% reduction after VNS Therapy

For patients on VNS Therapy®, SUDEP rates decreased over time

32% reduction in rates of SUDEP

In a retrospective analysis, age-adjusted SUDEP rates decreased over time from years 1 to 2
(2.47/1000 person-years) to years 3 to 10 (1.68/1000 person-years).10

SUDEP=sudden unexpected death in epilepsy

The nerve to choose a treatment that won't contribute to CNS adverse effects

VNS Therapy® is a safe, well-tolerated adjunctive treatment option that can improve your patients’ seizure control without contributing to anti-seizure medication (ASM) toxicity.

As an adjunctive treatment
with no drug interactions, VNS Therapy may help reduce the number and dosage of ASMs in your
patient’s regimen.13

VNS Therapy™ has proven safety and tolerability

VNS Therapy® has proven safety and tolerability

The most common side effects occur only during stimulation and typically diminish over time.11,12 The most common side effect of the surgical procedure is infection.13

VNS Therapy® has no neurotoxic effects or drug interactions11,13

Access resources to support your practice and patients

Access resources to support your practice and patients

Watch real-life patient testimonials

Watch real-life patient testimonials

References: 1. Thurman DJ, Logroscino G, Beghi E, et al. Epilepsia. 2017;58(1):17-26. 2. Mula M, Zaccara G, Galimberti CA, et al. Epilepsia. 2019;60:1114-1123. 3. Alsfouk BAAA, Brodie MJ, Walters M, et al. JAMA Neurol. 2020;77(5):574-581. 4. Chen Z, Brodie MJ, Liew D, et al. JAMA Neurol. 2018;75(3):279-286. 5. Data on file, LivaNova, Inc., Houston, TX. 6. Datta P, Galla KM, Sajja K, et al. Epilepsy Behav. 2020;111:107280. doi: 10.1016/j.yebeh.2020.107280. 7. Elliot RE, Morsi A, Tanweer O, et al. Epilepsy Behav. 2011;20(3):478-483. 8. Englot DJ, Hassnain KH, Rolston JD, et al. Epilepsy Behav. 2017;66:4-9. 9. Spindler P, Bohlmann K, Straub HB, et al. Seizure. 2019;69:77-79. 10. Ryvlin P, So EL, Gordon CM, et al. Epilepsia. 2018;59(3):562-572. 11. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415-418. 12. Morris GL, Mueller WM. Neurology. 1999;53(7):1731-1735. 13. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX.